New Releases from NCBI BookshelfTrastuzumab Deruxtecan (Enhertu): Indication: As monotherapy, is indicated for the treatment of adult patients with unresectable, locally advanced or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen: Reimbursement Recommendation [Internet].Trastuzumab Deruxtecan (Enhertu): Indication: As monotherapy, is indicated for the treatment of adult patients with unresectable, locally advanced or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen: Reimbursement Recommendation [Internet].
Canada’s Drug Agency (CDA-AMC) recommends that Enhertu be reimbursed by public drug plans for the second-line treatment of adult patients […]
